Chimerix Inc reports results for the quarter ended in September 30 - Earnings Summary

• Chimerix Inc CMRX.OQ reported a quarterly adjusted loss of 26 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -27 cents. The mean expectation of five analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -24 cents to -23 cents per share.

• Revenue rose 136.4% to $26.00 thousand from a year ago; analysts expected $75.00 thousand.

• Chimerix Inc's reported EPS for the quarter was a loss of 26 cents​.

• The company reported a quarterly loss of $22.88 million.

• Chimerix Inc shares had risen by 8.6% this quarter and gained 4.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Chimerix Inc is $6.00

This summary was machine generated from LSEG data November 7 at 02:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)